Eos Energy Enterprises, Inc. Announces Proposed Convertible Senior Notes Offering

Eos Energy Enterprises, Inc. Announces Proposed Convertible Senior Notes Offering GlobeNewswire November 18, 2025 EDISON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”) today announced its intention to offer, subject to market and other conditions, $500,000,000 aggregate principal amount of convertible senior notes due 2031 (the […]

Nia Tero Celebrates Indigenous-Led Victory in the Demarcation of Kaxuyana-Tunayana and Additional Territories

Today's announcement results in stronger protections and greater self-determination for Indigenous peoples in 20 areas, with 4 Indigenous Lands reaching final demarcation in the Amazon, representing a total of 2.4 million hectares. Nia Tero, an international organization solely focused on supporting Indigenous Peoples' guardianship of their homelands, celebrates with the Indigenous people of the Kaxuyana-Tunayana

Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for thefourth quarter and fiscal year 2025. https://mma.prnewswire.com/media/2561044/Dolby_Logo.jpg “We finished FY25 strong, growing Dolby Atmos, Dolby Vision and imaging patents, and expanding our addressable market with momentum in Dolby OptiView and the introduction of a new imaging patent pool for content streamers,” said Kevin Yeaman,

Jazz Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT. An audio webcast of the fireside chat will be available via the

DuPont Announces Early Results of Tender Offer for Senior Notes

DuPont (NYSE: DD) announced today the early results of its previously announced tender offer (the “Tender Offer”) to purchase for cash up to $739,256,000 aggregate principal amount (the “Maximum Tender Amount”) of its 5.419% Notes due 2048 issued on November 28, 2018 (the “2048 Notes”). The Tender Offer is being made pursuant to the terms

BROOKDALE ANNOUNCES CHIEF OPERATING OFFICER

Tenured Leader Brings 40 Years of Senior Living Experience to Operations Brookdale Senior Living Inc. (NYSE: BKD) (“Brookdale” or the “Company”) is announcing that Mary Sue Patchett, current Interim Executive Vice President – Community and Field Operations, has been named Chief Operating Officer effective December 1st. Ms. Patchett brings 40 years of senior living operations

Jacobs Appoints Global Technology Leader Diane Bryant to Board of Directors

Jacobs (NYSE: J) today announced the appointment of Diane Bryant to its Board of Directors, effective immediately. Bryant is a distinguished technology executive with more than three decades of leadership experience spanning the global semiconductor industry, cloud computing services, artificial intelligence applications and technology-based healthcare solutions. Bryant is widely recognized as a transformative leader in

B. Riley Financial Reports First Quarter 2025 Results

B. Riley Financial, Inc. (NASDAQ: RILY) (“BRF” or the “Company”), a diversified holding company, today announced the filing of its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025. Bryant Riley, Chairman and Co-Chief Executive Officer of B. Riley Financial, commented: “Our first quarter 2025 Form 10-Q filing marks an important

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests a profound radiologic response

Scroll to Top